GlassScriptPhysician profile
John C Novak
NPI 1619195880
$112,628.04
in general payments reported to CMS, 2019-2025
13 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.17 · 2020: $5,708 · 2021: $11.34 · 2022: $14K · 2023: $32K · 2024: $40K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Consulting Fee: $17K · Honoraria: $16K · Travel and Lodging: $8,701 · Food and Beverage: $3,467 · Education: $64.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,180.00 |
| Consulting Fee | $17,000.00 |
| Honoraria | $15,633.35 |
| Travel and Lodging | $8,701.30 |
| Food and Beverage | $3,466.63 |
| Education | $64.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $57,106.90 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amylyx Pharmaceuticals, INC. | $19,798.65 | 2023-2024 | Relyvrio |
| Tanabe Pharma America, INC. | $17,336.18 | 2023-2025 | Radicava, Radicava Ors |
| Ucb, INC. | $11,870.57 | 2023-2025 | Zilbrysq, Rystiggo |
| Biohaven Pharmaceuticals, INC. | $5,707.50 | 2020 | |
| Edw Pharma, INC. | $299.81 | 2022-2023 | Tiglutik |
| Astrazeneca Pharmaceuticals LP | $203.06 | 2025 | Wainua |
| Alexion Pharmaceuticals, INC. | $114.42 | 2025 | Ultomiris |
| Biogen, INC. | $75.79 | 2021-2024 | |
| Emd Serono, INC. | $71.90 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $17.99 | 2022 | |
| Medtronic Vascular, INC. | $14.30 | 2019 | |
| Philips North America LLC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Novak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.